|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Nuclear PKM2 subsequently bound to Oct4 and promoted the expression of cancer stemness-related genes, which might enrich the cancer stem cell population under the metabolic stress.
|
29408265 |
2018 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
These transformed cells, termed as miPS-RM9CM, displayed CSCs properties, including spheroids morphology and expression of both stemness genes and cancer stem cells surface markers, such as Oct3/4, Sox2, Nanog, Klf-4, c-Myc, CD44, and CD133.
|
30210930 |
2018 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Overall, an association between expression of OCT4 and pseudogenes and cancer prognosis were established, which may serve as a therapeutic target for various human cancers.
|
30287838 |
2018 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
More importantly, the expression levels of epithelial-mesenchymal transition biomarkers (N-cadherin and vimentin) and cell stemness biomarkers (nanog, sox2, and oct3/4) considerably increased in HepG2 with dopamine-induced SULT1A3/4, whereas in L02, epithelial-mesenchymal transition and cancer stem cell-associated proteins were contrarily decreased.
|
29025375 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Finally, we analyzed the expression and clinical significance of epithelial-to-mesenchymal transition (EMT) markers (E-cadherin and N-cadherin) and cancer stem cell (CSC) markers (Nanog, Oct-4, and Sox-2) in CRC tissues.
|
29081665 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The cell viability of mammospheres were evaluated by MTT assay and the OCT4 expression, a cancer stem cells marker, was verified by immunocitochemistry.
|
27671309 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In agreement, we find that FUT9 silencing decreases the expression of the colorectal cancer TIC marker CD44 and the level of the OCT4 transcription factor, which is known to support cancer stemness.
|
29196508 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
We further demonstrated that inactivation of p38 is a potential mechanism contributing to acquisition and maintenance of cancer stem cell properties in non-small cell lung cancer (NSCLC) cells. p38, in particular the p38γ and p38δ isoforms, suppresses the cancer stem cell properties and tumor initiating ability of NSCLC cells by promoting the ubiquitylation and degradation of stemness proteins such as SOX2, Oct4, Nanog, Klf4 and c-Myc, through MK2-mediated phosphorylation of Hsp27 that is an essential component of the proteasomal degradation machinery.
|
28460458 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival and reduced tumor size but also selectively eliminated the OCT4-positive cancer stem cells.
|
29141221 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Here, we initially showed that HBV stimulates the production of cancer stem cells (CSCs)-related markers (CD133, CD117 and CD90) and CSCs-related genes (Klf4, Sox2, Nanog, c-Myc and Oct4) and facilitates the self-renewal of CSCs in human hepatoma cells.
|
28455240 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The gene and protein expression levels of pluripotent stem cell markers (Tra-1-60, Oct4, Nanog) and cancer stem cell markers (CD133, CD44) were up-regulated in transduced Rbc51 cells compared to control cells.
|
27856246 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Real-time PCR was used to determine the expression levels of several reported cancer stem cell (CSC) markers, including CD44, CD133, ALDH1 and OCT4, in three OSCC cell lines.
|
28215944 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification |
BEFREE |
BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
|
28645561 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells (CSCs) are responsible for the resistance of osteosarcoma to chemotherapy and OCT4, SOX2 and SSEA4 have been used to identify CSCs in osteosarcoma.
|
28934267 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Octamer-binding transcription factor 4 (Oct4) protein, encoded by the POU class 5 homeobox 1 gene, is important in maintaining self-renewal of pluripotent stem cells, and is closely associated with cancer.
|
28123573 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells were analyzed using the marker Oct-4 to improve an understanding of the proliferative ability of cancer stem cells under various pathological conditions, which may lead to the development of novel cancer therapeutics.
|
29142598 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Cancer Stem Cells (CSCs), which in some cases express markers of pluripotency (e.g., Oct-4), share many of the molecular features of normal stem cells.
|
27730468 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line.
|
28454439 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The expression of OCT4 in cancer tissues and cell lines appeared to be highly controversial since it was believed that OCT4 is exclusively expressed in embryonic stem/embryonic carcinoma cells.
|
29022482 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Bmi-1, CD133, Nanog and Oct-4 have been reported as cancer stem cell (CSC) markers in head and neck squamous cell carcinoma (HNSCC).
|
28220856 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In order to investigate the potential of Sox2-Oct4 transcription factor decoy (TFD) strategy for differentiation therapy, mouse embryonic stem cells (mESCs) were used in this study as a model of cancer stem cells (CSCs).
|
28833847 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
A similar treatment also modulated numerous microRNAs (miRs) including one regulator of Oct4 as well as miRs involved in oncogenesis and/or malignancy, with only a few estrogen-induced miRs.
|
27959387 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct4 was reported to be one of the most important pluripotency transcription factors in the biology of stem cells including cancer stem cells, and progressed malignant cells.
|
28426762 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumorspheres derived from epidermal growth factor receptor (EGFR)-mutant HCC827 and EGFR wild-type A549 cells expressing higher cancer stemness markers (CD133, Oct4, and Nanog) were used as cancer stemness models.
|
28787001 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells.
|
28529558 |
2017 |